- QMB MEETING 2018
- MEDSCI NZ Congress 2018
- AWCBR
- QMB/ASI-NZ IMMUNOLOGY
- QMB Satellite CANCER
- QMB Satellite DRUGS &, DEVICES
- QMB Satellite MARINE BIOLOGY
- QMB Satellite PLANT
- QMB Satellite GENE TECHNOLOGIES
- QMB Satellite BIOINFORMATICS
- QMB/AWCBR BRAIN DISEASES
- ASCEPT
- Fashionomics
- Awards
- Careers Development Workshop
- Social Functions
- Poster Sessions and Abstract Submission
- Accommodation
- Registration
ASCEPT
Wednesday 29th Aug- Friday 31st Aug, 2018
Download the ASCEPT programme here
The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ scientific meeting promotes the work of students and professionals predominantly working in New Zealand.
The annual meeting comprises experimental and clinical pharmacology research, symposiums and exciting plenary sessions. ASCEPT has a strong focus on supporting students and up and coming researchers in the fields of clinical and experimental pharmacology.
Meeting updates here.
Meeting flyer here.
Abstract submission template here.
Invited Speakers
Carl Kirkpatrick, Monash University, Australia
Catherine Sherwin, University of Utah, USA
Jen Martin, University of Newcastle, NSW, Australia.
Michelle Glass, University of Auckland, NZ
Mary Jane McCarthy, Institute of Environmental Science and Research, NZ
Karen Oldfield, Medical Research Institute of NZ
Symposium: Medicinal Cannabis or Cannabis as a Medicine
Cannabis use has been reported now for thousands of years as a recreational agent and potential therapeutic. In the USA, cannabis appeared in the United States Pharmacopoeia for the first time in 1851. Federal restrictions on its use though began in 1937 and prohibition occurred with the Controlled Substances Act of 1970. A similar pathway was followed in a many developed nations. Since the legalisation of cannabis in California for medicinal purposes in 1996 however there has been a global push for recognition of “medicinal cannabis”. New Zealand is going through this process itself with a select committee currently investigating an amendment to the Misuse of Drugs act that would enable terminally ill patients to possess cannabis and develop a regulatory framework for the manufacture, import and supply of “medicinal cannabis”, but at this stage there is no definition of “medicinal cannabis”. This symposium will provide an overview of the current situation in New Zealand (Prof Michelle Glass, University of Otago), describe the development of the bioassays and technology needed to develop pharmacy grade products and run clinical trials in New Zealand (Dr Mary-Jane McCarthy, ESR), and the current attitudes of GPs and health care providers in New Zealand (Dr Karen Oldfield,MRINZ). The symposium will be rounded out by Prof Jennifer Martin, the Chair of Clinical Pharmacology at the University of Newcastle, the PI on Australia’s first medicinal cannabis trial for terminally ill adult cancer patients. She will talk about the clinical challenges of using cannabinoids as medicine, and their experiences so far.
NZ Section committee
Assoc Prof Nuala Helsby (Chair), Dr Kathryn Burns (Conference convenor), Dr Chris Cameron (Secretary), Dr Hesh Al-Sallami (Treasurer), Prof Michelle Glass
